EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders

Balapal S Basavarajappa iD, Shivakumar Subbanna

Biomolecules · 13.10.2024 · 14 (10) · 1296

DOI: 10.3390/biom14101296 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 13.10.2024. Verfasst von Balapal S Basavarajappa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA. Hauptthemen laut MEDLINE: Cannabis, Cannabinoids, Neuroprotective Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, NIH HHS, NIH/NIAAA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabis sativa is known for producing over 120 distinct phytocannabinoids, with Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) being the most prominent, primarily in their acidic forms. Beyond Δ9-THC and CBD, a wide array of lesser-known phytocannabinoids, along with terpenes, flavonoids, and alkaloids, demonstrate diverse pharmacological activities, interacting with the endocannabinoid system (eCB) and other biological pathways. These compounds, characterized by phenolic structures and hydroxyl groups, possess lipophilic properties, allowing them to cross the blood–brain barrier (BBB) effectively. Notably, their antioxidant, anti-inflammatory, and neuro-modulatory effects position them as promising agents in treating neurodegenerative disorders. While research has extensively examined the neuropsychiatric and neuroprotective effects of Δ9-THC, other minor phytocannabinoids remain underexplored. Due to the well-established neuroprotective potential of CBD, there is growing interest in the therapeutic benefits of non-psychotropic minor phytocannabinoids (NMPs) in brain disorders. This review highlights the emerging research on these lesser-known compounds and their neuroprotective potential. It offers insights into their therapeutic applications across various major neurological conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabisCannabinoidsNeuroprotective AgentsHumansAnimalsNervous System DiseasesCannabidiolBlood-Brain BarrierDronabinol

Stichwörter der Autor:innen

Alzheimer’s diseaseHuntington’s diseaseParkinson’s diseasealcohol-use disorderscannabinoid receptorsendocannabinoidsepilepsyneurodegenerative disorderspsychiatric disorderssubstance-use disorders

Substanzen

CannabinoidsNeuroprotective AgentsCannabidiolDronabinol

Autor:innen und Institutionen

  • Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.
  • Department of Psychiatry, New York University Grossman School of Medicine, New York, NY 10016, USA.

ORCID-Profile: Balapal S Basavarajappa

Förderung

  • NIAAA NIH HHS
  • NIH HHS
  • NIH/NIAAA

Zitieren

APA

Basavarajappa, B. S., & Subbanna, S. (2024). Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders. Biomolecules, 14(10), 1296. https://doi.org/10.3390/biom14101296

Vancouver

Basavarajappa BS, Subbanna S. Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders. Biomolecules. 2024;14(10):1296. doi:10.3390/biom14101296

BibTeX
@article{Basavarajappa2024,
  author = {Basavarajappa, Balapal S and Subbanna, Shivakumar},
  title = {Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders},
  journal = {Biomolecules},
  year = {2024},
  volume = {14},
  number = {10},
  pages = {1296},
  doi = {10.3390/biom14101296}
}
Kostenlos starten →